

Date: 2022-04-19

Cancelled Before Active Statement

EudraCT number: 2012-002573-62

Full title of the study: Doppler quantitative evaluation and follow-up over 12 months in RA patients with moderate and high disease activity who are candidates for biologic add-on therapy with Adalimumab

Sponsor: Karolinska Institutet

Contact person: hamed.rezaei@sll.se

Product: Adalimumab

Date of the early termination of the trial: 2017-09-01

Statement on discontinuation of the study: Study terminated because it was difficult to recruit patients. No participants were recruited.

Sofie Possmark Coordinator Compliance & Data Office Research Support Office Karolinska Institutet Sweden